• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:

    公开号:NL1037485A
    申请号:NL1037485
    申请日:2009-11-20
    公开日:2010-05-28
    发明作者:Jie Zhu；Judith Janneke Firet
    申请人:Synthon Bv；
    IPC主号:
    专利说明:

    LEVOCETIRIZINE BY MENTHYL INTERMEDIATE
    Cetirizine, chemically 2- [4- [(4-chlorophenyl) phenylmethyl] piperazin-1-yl] ethoxy] acetic acid, or the formula (A)
    is an useful pharmaceutical active ingredient. It is an antihistamine whose principal effects are mediated through selective inhibition or Hi receptors. This anti-allergy drug is marketed by the company UCB (which is also the originator of the drug) and / or Pfizer under the brand name Zyrtec®, as a dihydrochloride salt (often referred to as "cetirizine hydrochloride").
    The drug is indicated for the relief of symptoms associated with seasonal allergic rhinitis or perennial allergic rhinitis, as well as for the treatment of uncomplicated skin manifestations or chronic idiopathic urticaria in adults and children 6 months of age and older.
    Cetirizine has one asymmetric carbon, therefore it may be resolved into enantiomers. The pharmaceutically active enantiomer in the racemic cetirizine is the levocetirizine, which is the (R) enantiomer or cetirizine. A medicament including levocetirizine was launched in the first quarter of 2001 in Germany followed by a pan-European launch.
    Levocetirizine is also marketed as the dihydrochloride salt, under the brand name Xyzaal®.
    Cetirizine was disclosed in US 4,525,358 (EP 58146). Levocetirizine was specifically disclosed in GB2225321. The method of use of levocetirizine has been disclosed in US 5,698,558 (EP 663828).
    Levocetirizine may be obtained by resolution of the cetirizine enantiomers as generally suggested, e.g., in WO 94/06429. However, the effectiveness of such a process is apparently not high and therefore it is preferred to make levocetirizine from an enantiopure intermediate.
    One such useful intermediate is the compound of formula (4)
    The presence of a quaternary carbon in the formula (4) indicates that the compound may be obtained as a single enantiomer, particularly as the (R) enantiomer. Resolution of the intermediate (4) into enantiomers by L-tartaric acid as well as the process for making levocetirizine from the corresponding enantiomer or (4) was disclosed in GB2225321. However, the yield and effectiveness of the resolution is insufficient, as shown in US 5,478,941.
    [0007] The useful starting material for making the compound (4) is the well-known and commercially available compound or formula (1),
    Similarly as the above compound (4), the compound (1) may be obtained as a racemate or as a single enantiomer, particularly as the (R) enantiomer. It is known that the racemic compound (1) can be resolved into enantiomers by a fractional crystallization, preferably by the crystallization of salts with L-tartaric acid. (see US 5,478,941). This makes the compound (1) an important intermediate, particularly in the synthesis of an enantiomerically pure (4).
    In a known process for making compound (4) disclosed in EP 617028 (US 5,478,941), the compound of formula (1) is subject to a condensation with the N-sulfonated bis-chloroethylamine compound or formula (2),
    to form the compound or formula (3).
    The compound (3) is then protected to form the compound or general formula (4).
    In principle, one could also expect an unprotected compound of the formula (5a)
    might be used for coupling with the compound (1). This would avoid the deprotection step and form the compound (4) directly. But this option is not satisfactory. First, the compound (5a) is an extremely toxic compound ("mustard gas"), and second the reaction is accompanied by a large amount of side products, particularly from the self-condensation of the compound (5). Thus, the use of an N-protected bis-haloethylamine is clearly preferable. But other potentially useful N-protected compounds, e.g. a carbonyl, alkyl or a triphenylmethyl protecting group, have been reported as unsatisfactory. US 5,478,941 and EP 955295 teach that the above-mentioned N-tosyl compound or formula (2) is the only useful compound for the coupling reaction with (1). The protected analogues (a carbonyl, alkyl, or trityl protecting group) caused important racemization of the compound (1) during the coupling reaction and / or the formation of undesired by-products.
    Opalka C.J. et al. (Synthesis 1995 (7), p. 766-768) reports that the coupling reaction failed if the amides of formula (6), being a carbon-terminated substituent, were used.
    Thus other protecting groups have proven to be unsuitable so far.
    It would be desirable to have an alternative process for making the compound or general formula (A), particularly for making the R-enantiomer, the levocetirizine.
    Summary of the Invention The present invention relates to the discovery of a convenient process and intermediates for making levocetirizine from achiral precursors. Considering a first aspect of the invention relates to a process for the making of levocetirizine, which comprises: a) providing a pair of diastereomers or a compound of formula (8)
    or an acid addition salt with a suitable inorganic or organic acid, Z is C1-C20 straight or branched alkyl / cycloalkyl / aralkyl / alkylaryl group, each of which groups can optionally be dispensed by one to four halogen, alkoxy, amino , and / or nitro groups and include the group At least one chiral carbon atom
    said pair being characterized by a single conformation on the chiral carbon (s) within the group Z and either R- or S-conformation on the chiral carbon outside the group Z
    b) resolving the pair of diastereomers of the compound (8) into single diastereomers and isolating the enantiomerically pure diastereomer having R-conformation on the chiral carbon outside the group Z c) converting, such as by hydrolysis, the single diastereomer of the compound ( 8) with R-conformation on the chiral carbon outside the group Z into (R) enantiomer of the compound (4)
    and d) converting the (R) enantiomer of the compound of the formula (4) into levocetirizine.
    In particular, the step a) comprises i) reacting a racemic compound or formula (1) with a compound or formula (7) in the presence of a base,
    where X is a leaving group reactive with an amine, for instance a halo group such as chloro or bromo group; or a sulphonyl group such as mesyloxy, besyloxy or tosyloxy group; and preferably X is a chloro group; and Z is as defined above.
    Alternately, the step a) comprises ii) reacting the compound of the formula (4) with a haloformate of the formula (9)
    X- C (= 0) - where X is a halogen group, preferably a chloro group and and are the same as defined above
    In a particular aspect, the compound of a formula (8) intois an acid addition salt with a suitable inorganic or organic acid, and one diastereomer or such salt is obtained by fractional crystallization from a suitable solvent.
    In a particular aspect, the diastereomer obtained from the above fractional crystallization is the diastereomer or the compound of formula (8) with R-conformation on the chiral carbon outside the group Z.
    Advantageously, the group Z is a menthyl group (2-isopropyl-5-methylcyclohexyl group), preferably with the conformation (1R, 2S, 5R) or (1S, 2R, 5S).
    In another aspect, the invention provides a process for converting the racemic compound (4) into enantiomers, such a process including the steps of a) converting the racemic compound (4) into a pair or diastereomers or a compound or formula (8)
    or an acid addition salt with a suitable inorganic or organic acid, Z is C1-C20 straight or branched alkyl / cycloalkyl / aralkyl / alkylaryl group, each of which groups can optionally be dispensed by one to four halogen, alkoxy, amino , and / or nitro groups and, the group includes at least one chiral carbon atom
    said pair being characterized by a single conformation on the chiral carbon (s) within the group Z and either R- or S-conformation on the chiral carbon outside the group Z
    b) resolving the pair or diastereomers of the compound (8) into single diastereomers having either R or S conformation on the chiral carbon outside the group Z c) converting, such as by hydrolysis, the single diastereomer of the compound (8) into single enantiomer of the compound (4)
    The Z group in the above process is preferably a (-) menthyl or a (+) - menthyl group.
    The compounds of formula (8), particularly any and each of diastereomers, including inclusive or said diastereomers, form a particular aspect of the present invention. Each of the above formulas includes acid addition salts or the compounds.
    In particular, the preferred compound of the formula (8) is the compound of the formula (8a),
    a single diastereomer, as well as an acid addition salt, especially the sulfate salt.
    Another aspect of the invention relates to the compounds of formulas (7) and (9). Typically X is chloro and Z is (+) - menthyl or (-) - menthyl group.
    Still another aspect of the invention relates to the use of the compounds of formula (8) and (7) in the making of levocetirizine and / or the compound of formula (4).
    Detailed Description of the Invention.
    The present invention deals with an alternative process for making the single, preferably (R), enantiomer or a compound or formula (4), which is the key intermediate in the synthesis or pharmaceutically useful compound levocetirizine. The process is characterized by using a specific optically active substituent in the course of the synthesis, which allows to resolve one of the intermediates in the synthesis or (4) into enantiomers without a need or using any optically active acid. As any process of making levocetirizine via the intermediate (4) requires the use of optically active acids as resolution agents, the finding that such acids are no more necessary is surprising. And in as much as the optically active substituent is preferably used in the synthesis of compound (4), the process can essentially serve two functions at once.
    As used, the chiral carbon in the methyl group bridging two phenyl groups in the compounds (1), (4) and (8) is called "chiral carbon outside group Z", regardless of whether group Z is actually present. All chemical formulas having such chiral carbon present include both mixtures of the enantiomers such as a racemate as well as single enantiomers.
    The "enantiomerically pure" enantiomers or diastereomers are compounds with at least 90% optical purity, preferably at least 95% optical purity, and including at least 98% and at least 99% optical purity. Similarly, all chemical formulas, e.g., (1) to (8), include the acid addition salts, unless explicitly stated to the contrary.
    In the first step of the process of the present invention, a compound of the formula (8) is provided as a pair or diastereomers. The compound of the formula (8) comprises a chiral group Z, which is C1-C20 straight or branched alkyl / cycloalkyl / aralkyl / alkylaryl group, each of which groups can optionally be supplied by one to four halogen, alkoxy, amino, and / or nitro groups. The group Z comprises at least one chiral carbon atom. In an important aspect, the chiral carbon atom (s) in the group Are the substituents oriented in a single way. i.e. there are no alternatives in the conformation of substituents around the chiral_carbon. On the other hand, the chiral carbon outside the group Z (the carbon bridging the phenyl groups) may have an orientation of substituents in either R- or S-configuration. As a result, the compound (8) is provided as a pair or diastereomers; if, for example, the group Z comprises one chiral carbon with the orientation (R) or substituents, the pair or diastereomers of the compound (8) have the conformation (R, R) and / or (S, R), resp.
    An advantageous example of the group Z is the menthyl group (2 isopropyl-5-methylcyclohexyl group). This group has three chiral carbons allowing for 8 stereo summers; any single combination or spatial arrangement or substituents is allowable, provided that the resulting conformation is singular; i.e. always a single stereo summer must be used. Advantageously, the menthyl group should have the same conformation as has the natural (-) menthol, i.e. (1R, 2S, 5R),
    such menthyl group will be denoted as (-) - menthyl group, or the opposite conformation corresponding to (+) - menthol, ie (1S, 2R, 5S), such menthyl group will be denoted as (+) -menthyl group .
    Another example of a suitable group Z is camphenyl group.
    The compound (8) may be obtained by various ways.
    In a first process, the compound (8) is obtained by a reaction of the racemic compound (4) with a haloformate of the formula (9)
    X-C (= 0) - where X is a halo group such as chloro or bromo group and preferably X is a chloro group; and Z is as defined above. Advantageously, the Z represents a single stereoisomer or a menthyl group, particularly (-) menthyl group, and X represents chlorine. Thus, the preferred compound for the reaction with the compound (4) is a menthyl chloroformate or the formula (9a).
    The reaction between compound (4) and (9) generally proceeds in an inert, preferably water-immiscible, solvent, eg in a hydrocarbon or a halogenated hydrocarbon, preferably under presence of a base, which may be advantageously an organic base, for instance a primary, secondary or tertiary amine. The reaction temperature may be ambient or close to ambient (0-50C) The side product (a salt of the amine) is conventionally removed by an extraction by water and the product is optionally isolated by the organic layer, eg by a removal of the solvent. The crude product may be purified, if necessary, or may be used in the next step in the crude state. The compound (8) may also be isolated as an acid addition salt.
    In a second process, the racemic compound or formula (1) reacts, generally in a liquid phase, with the compound or the general formula (7) to yield the compound or formula (8).
    In the formulas (7) and (8), Z is the same group as defined above; preferably, Z is a menthyl group.
    The compound (7) contains two equal leaving groups X that are reactive with the primary amine in the compound (1) to form the piperazine ring. Such groups X may be represented by a halogen group, or a sulphonyl group such as mesyloxy, besyloxy, anisylsulfonyloxy or tosyloxy group; preferably X is a chloro group.
    Thus, the preferred example of the compound of the general formula (7) is the compound of formula (7a),
    The reaction between compounds (1) and (7) proceeds in the presence of a base, which is preferably an organic base. In a convenient embodiment, a liquid organic base is employed, the liquid organic base also serves as the solvent of the reaction. The preferred liquid organic base is diisopropylethylamine. The reaction preferably proceeds at an elevated temperature, e.g., at a temperature between 50-150 ° C, suitably at reflux. Advantageously, potassium iodide may be added as an initiator. The reaction progress may be monitored by a suitable analytical technique, e.g., HPLC. After the reaction, the reaction mixture containing the product (8) may be used for the next step (advantageously, after removal of amine salts formed and / or after removal or at least part of the solvent) or is elaborated to isolate the reaction product (8).
    In a suitable way of isolation, the reaction mixture is partitioned between an aqueous and organic phase (the organic solvent may be conveniently a hydrocarbon or a chlorinated hydrocarbon) and the product is isolated from the organic phase. The crude product may be purified, if necessary, or may be used in the next step in the crude state. The compound (8) may also be isolated as an acid addition salt.
    If the preferred compound (7a) or (9a), respectively, is used, the reaction product is the compound or formula (8a),
    which comprises a pair of two diastereomers differing in the orientation of substituents around the chiral carbon outside the group Z (the carbon bridging the two phenyl groups) [0026] In a second step, the pair of diastereomers of the compound (8) is resolved to obtain a single diastereomer, preferably having the chiral methyl group in the (R) conformation; i.e., in the correct orientation for completing a levocetirizine synthesis.
    The compound (8), particularly the compound (8a), may be resolved into single diastereomers without a need or any resolution agent, i.e., e.g., without a need or an optically active acid. In practice, a suitable process comprises a fractional crystallization of the compound (8) from a suitable solvent. Another suitable process comprises chromatography on a suitable column, such as HPLC. Advantageously, but not necessarily, the compound (8) is first converted into a suitable acid addition salt before the fractional crystallization by contacting with a suitable acid in a suitable solvent, which may be the same or different from the solvent used for the crystallization. Examples of suitable acid addition salts are, without limitation, a hydrochloride, a hydrobromide, sulfate, phosphate, acetate, formate, maleate, fumarate, tartrate or oxalate etc .. Examples of suitable solvents for fractional crystallization are, without limitation, water a C 1 -C 6 aliphatic alcohol, a C 3 -C 8 aliphatic ketone, a C 2 -C 8 aliphatic or cyclic ether, C 2 -C 10 ester, C 1 -C 4 nitrile, and mixtures thereof.
    In the fractional crystallization, one diastereomer of the compound (8) preferentially precipitates and the second one preferentially remains in the solution. The word "preferentially" illustrates the fact that the precipitate and / or resolution does not include 100%, but comprises a majority, such as more than 70% of the desired enantiomer. The conformation of the diastereomer in the precipitated / crystallized product depends on the choice of the group Z, on the solvent and on the nature of the compound (8), i.e. whether the compound (8) is a base or a salt. The solid product obtained by crystallization may be advantageously, but not necessarily, the product with the desired (R) orientation on the chiral carbon atom outside the chiral group Z. It may be isolated by filtration and optionally washed and dried. The second of the pair of diastereomers that remained in the solution may be isolated by evaporation of the solvent.
    If the isolated product does not have sufficient optical purity, the fractional crystallization or any of the obtained fraction may be repeated.
    Typically, the preferred compound (8a) is fractionally crystallized as a base or is converted into a salt with sulfuric acid. If crystallized as a base, e.g. from an etheral solvent, the product with the desired (R) orientation preferentially remains in the solution. On the other hand, the sulfate salt crystallizes (e.g. from ethyl acetate and / or acetonitrile) as a solid preferentially with the (R) orientation, while the (S) diastereomer is concentrated in the solution.
    Any and each diastereomer of the compound (8) forms a particular aspect of the present invention.
    In the third step, the single diastereomer of the compound (8) is subject to a hydrolysis / solvolysis of the carbamate group. The hydrolysis is advantageously performed by an aqueous or alcoholic acid or by an aqueous alkali. The acid may be, e.g., hydrochloric or sulfuric acid. The "aqueous alkali" comprises an aqueous solution or suspension of lithium, sodium, potassium or calcium hydroxide or carbonate. The reaction may proceed in the presence of an inert co-solvent. The reaction product comprising the single, preferably the (R) - enantiomer of the compound (4) is then advantageously extracted by a water-insoluble organic solvent, preferably by ethyl acetate and / or toluene, and isolated from the organic phase. Side products, if any, may be efficiently removed if the above extraction is done under acidic or alkaline conditions.
    In an advantageous mode, the formed compound or formula (4) is isolated from the reaction mixture, and / or purified. It may be isolated as a free base or may be isolated after converting it into an acid addition salt with an organic or inorganic acid that is isolatable as a solid, preferably crystalline, product. An advantageous salt in this respect is the oxalate salt as it may be isolated as a stable crystalline material. The oxalate salt of the compound (4) is a suitable form that allows storage of the compound (4), particularly the (R) enantiomer, for an enhanced period of time. The single enantiomer of the compound (4) may also be isolated as a free base, which is preferably a solid product, for instance by a suitable extraction process.
    In an example, the reaction mixture is partitioned between an organic layer and acidified aqueous layer (in which the product concentrates), the aqueous layer is neutralized, the free base or (4) is extracted by an organic solvent and isolated from this solvent.
    The starting (4-chlorophenylphenylmethylamine or formula (1) and the compound of formula (4) are known, commercially available compounds.
    The compound of formula (7) may be obtained, for instance, by the condensation of the compound (5)
    and / or an acid addition salt, with a chloroformate compound or formula (9)
    (9) where X and Z have the above meaning. The preferred compound Ν, Ν-bis (2-chloroethyl) (-) menthyl carbamate or the formula (7a) is thus obtained by the reaction of the bis (2-chloroethyl) amine with a (-) menthylchlorofornate or formula (9a) .
    Similarly, one may prepare Ν, bis-bis (2-chloroethyl) (+) menthyl carbamate by the reaction of the bis (2-chloroethyl) amine with a (+) menthyl chloroformate.
    The reaction is advantageously performed in an inert solvent, e.g., in a hydrocarbon solvent or a halogenated hydrocarbon solvent, preferably in the presence of a base.
    Alternatively, the compound of formula (7) may be obtained from bis (2-hydroxyethyl) amine and a haloformate (9) according to the scheme
    under general conditions known in the art.
    The single (R) enantiomer of the compound of formula (4), as well as acid addition salts, prepared by the above process, may be converted to a levocetirizine compound by known means as described in the above cited patents .
    The invention is illustrated by the following nonlimiting examples.
    EXAMPLES
    Example 1: (preparation of menthyl carbamate)
    14.35 g (0.05 mol) of piperazine derivative of the formula (4) was dissolved in 100 ml of dried dichloromethane, followed by addition or 15 ml of (-) - menthyl chlorofornate dropwise, while stirring at room temperature. The addition was completed within 15 minutes. 7 ml of triethylamine was added in ~ 2 minutes. Mixture was further stirred over night. 200 ml of H2O was added, and the mixture was sirred for another 30 minutes. Layers were separated. Water layer was extracted again with dichloromethane (25 ml). Combined organic layer was concentrated in vacuo to give a oily / semi-solid material.
    Example 2: (chiral separation or free base)
    Z * is (1S) - (-) - menthyl A mixture containing 7.62 g of (+) carbamate (8a) in 30 ml of diethyl ether were stirred at ~ 4 ° C for 2 hours. Solid was collected by filtration and dried. Enantiomeric enriched solid was suspended again in 7.5 ml of diethyl ether and stirred for 2 hours at ~ 4 ° C.
    The solid was isolated by filtration and dried. Enriched solid was suspended again in 5 ml of diethyl ether and stirred for 6 hours at ~ 4 ° C. The isolated carbamate compound (l.Og) had a 97.5% in S enantiomeric purity.
    Example 3: (chiral separation or free base)
    Z * is (1S) - (-) - menthyl A mixture containing 5.48 g (+) of Carbamate (8a) in 25 ml of isopropyl ether were stirred at 40 ° C for 30 minutes. Formed suspension was stirred at ambient temperature for 3 hours, and further at ~ 4 ° C overnight. Enriched solid was isolated by filtration and dried.
    The isolated solid was suspended in 10 ml isopropyl ether. The suspension was stirred for 2 hours at 4 ° C. The solid was isolated again by filtration and dried.
    The above procedure was repeated twice using 5 ml of isopropyl ether.
    The isolated carbamate compound (1.36g) had a 96% in S enantiomeric purity.
    Example 4: (chiral separation or free base)
    Z * is (1S) - (-) - menthyl A mixture containing 11.84 g (+) of Carbamate (8a) in 40 ml of isopropyl ether was stirred at ambient temperature for 4 hours. Enriched solid was isolated by filtration and dried.
    The isolated solid was suspended in 20 ml of isopropyl ether. The suspension was stirred at ambient temperature for 4 hours. The solid was isolated again by filtration and dried.
    The above procedure was repeated once using 25 ml of isopropyl ether.
    The isolated carbamate compound (2.62g) had a 96.5% in S enantiomeric purity.
    Example 5: (chiral separation or free base)
    Z * is (1S) - (-) - menthyl A mixture containing 3.91g (+) Carbamate in 10 ml isopropyl ether was refluxed for 1 hour. Then it was stirred at ambient temperature for 4 hours. Solid was collected by filtration and dried. Enriched carbamate was suspended in 5 ml of isopropyl ether. The suspension was refluxed for 1 hour. Then it was stirred at ambient temperature for 4 hours. Solid was collected by filtration and three at 40 ° C under vacuum. The isolated carbamate compound (1.22g) had a 97.2% in S enantiomeric purity.
    Example 6: (chiral separation or sulphuric acid salt)
    Z * is (1S) - (-) - menthyl
    Crude (-) menthyl carbamate (prepared from 14.35 g of piperazine derivative) was dissolved in 200 ml of ethyl acetate. With stirring at room temperature, 4.9 g of sulphuric acid was added dropwise in ~ 2 minutes. Mixture was stirred for 2 hours. 25 ml of acetonitrile was added, and the mixture was further stirred over night. Solid was filtered off, which showed an enantiomeric purity of -73%.
    Crude solid was refluxed in a mixed solvent or 150 ml of ethyl acetate and 25 ml of acetonitrile for 1 hour and stirred at room temperature for 2 hours. Solid was collected by filtration.
    The washing process was repeated for 4 times. Final obtained solid showed> 98% in R enantiomeric purity. 11.41 g of solid was obtained after drying ('40%).
    Example 7: (hydrolysis of the carbamate)
    Z * is (1S) - (-) - menthyl 2.5 g of carbamate salt was suspended in 5 ml of isopropanol. With stirring at room temperature, 2 ml of sulphuric acid was added dropwise. Formed solution was stirred at 90 ° C (heating temp.) For 5 hours.
    After cooling down to room temperature, 20 ml of isopropyl ether and 20 ml of water were added. Mixture was stirred for 20 minutes. Separated aquous layer was neutralized to pH 8, by addition or a 2 N NaOH solution. Mixture was extracted with ethyl acetate (2x20 ml). Combined ethyl acetate layer was washed with H20, brine, dried and concentrated to give an oily material. The oil was re-dissolved in 10 ml of three toluene. After partly evaporated on rotor vapor, solid was precipitated. The solid was filtered off. 960 mg of a solid product was obtained after drying at 40 ° C in vacuo over night.
    Example 8
    To a suspended bis (chloroethyl) amine HCl salt (5.0 g) in 30 ml of dry dichloromethane, with cooling (ice water) and stirring, (-) - menthyl chloroformate (6.4 ml) was added dropwise. The addition was completed within 20 minutes followed by addition of triethylamine (8.9 ml) in 55 minutes. The mixture was further stirred at room temperature for 30 minutes. Water (10 ml) was added, and the mixture was stirred for 20 minutes. dichloromethane layer was washed with HCl 1M (10 ml), brine (10 ml), dried and concentrated in vacuo to give an oily product (7.5 g, -83% yield).
    Step 2 - Compound (8a)
    A mixture containing (4-chlorophenyl) phenyl methylamine hydrochloride salt (4.1 g), bis (chloroethyl) amine menthyl carbamate (7.0 g), potassium iodide (1.7 g) and diisopropyl ethylamine (10 ml) was stirred at 120 ° C (140 ° C oil bath) for 6 hours.
    After cooling down, 60 ml of dichloromethane was added. Mixture was stirred at ambient temperature for 30 minutes and the organic layer was separated. The separated organic layer was washed with HCl solution (1M, 30 ml) and brine (20 ml). It was three and concentrated to give an oily material (10 g).
    Step 3 - Resolution of the compound (8a)
    Above crude material was dissolved in ethyl acetate (40 ml). With stirring at room temperature, sulphuric acid (0.88 g) was added dropwise and sticky solid was appeared. The stirring was stopped for a while, and the supernatant was decanted.
    The sticky solid was triturated in diisopropyl ether (10 ml) over night. Solid was filtered off, which was -5.5 g in total, after drying.
    The solid was suspended in a mix solvent (10 ml of acetonitrile and 60 ml of ethyl acetate) and stirred with refluxing for ~ 1 hour. Solid was filtered off. The washing process was repeated twice. Desired salt was obtained (1.1 g, enantiomeric purity is> 97.1%).
    Each of the patents, patent applications, and journal articles mentioned above are incorporated by reference. The invention having been described it will be obvious that the same may be varied in many ways and all such modifications are contemplated as being within the scope of the invention as defined by the following claims.
    权利要求:
    Claims (15)
    [1]
    A method for making levocetirizine, comprising: a) providing a pair of diastereomers of a compound of formula (8)

    [2]
    The method of claim 1, wherein the step a comprises: i) reacting a racemic compound of formula (1) compound of formula (7) in the presence of a base

    [3]
    The method of claim 1, wherein step a) comprises ii) reacting the compound of formula (4) with a halogen formate of formula (9)

    [4]
    The method of claims 1-3, wherein the compound of formula (8) is the acid addition salt with a suitable inorganic or organic acid, and one diastereomer of such a salt is obtained by fractional crystallization with a suitable solvent.
    [5]
    The method according to claims 1-4, wherein the diastereomer obtained with the aforementioned fractional crystallization is the diastereomer of the compound of formula (8) the R conformation on the chiral carbon atom outside the group Z.
    [6]
    The method according to claims 1-5, wherein the group Z is a menthyl group (2-isopropyl-5-methylcyclohexyl group), preferably with the conformation (IR, 2S, 5R) or (1S, 2R, 5S) or a camphenyl group.
    [7]
    A process for converting the racemic compound (4) into enantiomers, the process comprising the steps of: a) converting the racemic compound (4) into a pair of diastereomers of a compound of formula (8)

    [8]
    The method of claim 7, wherein the Z group is a (-) menthyl group or a (+) menthyl group or a camphenyl group.
    [9]
    The method of claims 1-8, wherein the acid addition salt is the sulfate salt.
    [10]
    10. Compound of formula (8)

    [11]
    A compound according to claim 10 in the form of an acid addition salt, preferably the sulfate salt.
    [12]
    A compound according to claim 10 or 11 which is the compound of the formula (8a)

    [13]
    13. The compound of formula (7)

    [14]
    A compound of formula (9) X-C (= O) -O-Z (9) wherein X is a halogen group, preferably a chlorine group, and Z is a C 1 -C 20 straight or branched alkyl / cycloalkyl / aralkyl / alkaryl group wherein each of the groups may be optionally substituted by one to four halogen, alkoxy, amino and / or nitro groups, and wherein the group Z comprises at least one chiral carbon atom.
    [15]
    The use of a compound according to claims 11-14 in making levocetirizine and / or the compound of formula (4).
    类似技术:
    公开号 | 公开日 | 专利标题
    RU2433122C2|2011-11-10|Synthesis of acylaminoalkenylamides, suitable as antagonists of substance p
    US8334385B2|2012-12-18|Process for the preparation of R-sitagliptin and its pharmaceutically acceptable salts thereof
    US8703955B2|2014-04-22|Process for the resolution of isoquinoline derivatives
    KR20050089839A|2005-09-08|A process for preparing duloxetine and intermediates for use therein
    JP5503546B2|2014-05-28|Separation of 4,5-dimethoxy-1- | -benzocyclobutane
    US7915421B2|2011-03-29|Method for preparing phenyl acetic acid derivatives
    AU2004213104B2|2010-07-08|Indazolamides with analgesic activity
    US7612215B2|2009-11-03|Process for preparing 2-oxo-1-pyrrolidine derivatives by intramolecular allylation
    CN101356162A|2009-01-28|Optically active carbamates, process for preparation thereof and use thereof as pharmaceutical intermediates
    CA2561866A1|2006-01-12|Process for the optical resolution and recycling of tomoxetine
    EP2062881B1|2011-02-23|Process for making N-|piperazines
    FR2597100A1|1987-10-16|PYROGLUTAMIDE DERIVATIVES
    WO2009062036A2|2009-05-14|Processes for preparing levocetirizine and pharmaceutically acceptable salts thereof
    NL1037485C2|2010-07-27|Levocetirizine by menthyl intermediate.
    US20110251389A1|2011-10-13|Process For Making N-|piperazines
    WO2014009964A1|2014-01-16|Process for enantiomeric enrichment of 2 ', 6 ' - pipecoloxylidide
    CA2143249C|2002-02-26|Substituted sulfonamides; process for preparing the same and pharmaceutical compositions containing them
    WO1994002473A1|1994-02-03|N-cycloalkylpiperazine derivatives, methods of obtaining them and pharmaceutical compositions containing them
    EP3233814A2|2017-10-25|Novel process for the preparation of ranolazine
    JP3187905B2|2001-07-16|Process for producing racemic and optically active 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid and precursors thereof
    US20100145049A1|2010-06-10|Process for making n-|piperazines
    HU0102567A2|2005-03-29|Resolution process for producing |-|-2-hydroxy-2-| acetic acid
    EP1143971B1|2004-06-02|Substituted 1-|-3-|-isothioureas, their preparation and therapeutic use
    JPH10195038A|1998-07-28|Benzenesulfonamide derivative and medicine containing the same derivative
    FI56674C|1980-03-10|REFERENCE FOR THERAPEUTIC USE OF THERAPEUTIC THERAPEUTIC DIPHENYL METHODYLAMINE
    同族专利:
    公开号 | 公开日
    WO2010057515A1|2010-05-27|
    NL1037485C2|2010-07-27|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    GB1528321A|1975-07-07|1978-10-11|Leo Ab|Acylation process for the preparation of phenolic n,n-di-substituted carbamate esters|
    GB8621268D0|1986-09-03|1986-10-08|Univ Strathclyde|Separation of substances|
    US5756774A|1997-02-04|1998-05-26|Bittman; Robert|Synthesis of myo-inositol phosphates|
    CA2319837C|1998-02-12|2009-10-27|De Montfort University|Hydroxylation activated drug release|
    US6642222B2|1998-10-28|2003-11-04|Abbott Laboratories|Pyrano, piperidino, and thiopyrano compounds and methods of use|
    JP2002249487A|2001-02-22|2002-09-06|Sumitomo Chem Co Ltd|4-piperazine derivative, optically active acid addition salt of the same, method for producing them and optically active 1-[phenylmethylpiperazine which uses them|
    US7579335B2|2005-01-10|2009-08-25|Glaxo Group Limited|Androstane 17α-carbonate derivatives for use in the treatment of allergic and inflammatory conditions|
    HU227074B1|2005-12-08|2010-06-28|Egis Gyogyszergyar Nyrt|An optically active carbamic acid derivative, method for producing the same and use as a pharmaceutical intermediate|
    PL2062881T3|2007-11-21|2011-07-29|Synthon Bv|Process for making N-piperazines|WO2012101475A1|2011-01-27|2012-08-02|Jubilant Life Sciences Limited|An improved process for the preparation of antihistaminic drugs via a novel carbamate intermediate|
    法律状态:
    2013-06-12| V1| Lapsed because of non-payment of the annual fee|Effective date: 20130601 |
    优先权:
    申请号 | 申请日 | 专利标题
    EP2008009977|2008-11-21|
    PCT/EP2008/009977|WO2010057515A1|2008-11-21|2008-11-21|Levocetirizine by menthyl intermediate|
    [返回顶部]